伊沙佐米用于未接受自体干细胞移植的新诊断多发性骨髓瘤诱导后维持治疗:III期TOURMALINE-MM4试验
TOURMALINE-MM4是一项III期双盲安慰剂对照试验,评估口服蛋白酶体抑制剂伊沙佐米作为维持治疗用于未接受自体干细胞移植的新诊断多发性骨髓瘤患者。
要点
- 伊沙佐米维持治疗降低34.1%的进展或死亡风险,中位PFS 17.4 vs 9.4个月。
- 诱导后达完全或非常好的部分缓解患者获益更显著(中位PFS 25.6 vs 12.9个月)。
- 常见不良事件为恶心、呕吐、腹泻,3级及以上不良事件发生率36.6% vs 23.2%。
核心结论
- 伊沙佐米维持治疗可延长未接受ASCT的新诊断多发性骨髓瘤患者的PFS,且无意外毒性。
研究设计与样本
- III期双盲安慰剂对照试验,按3:2随机分配至伊沙佐米组(n=425)或安慰剂组(n=281)。
- 患者为接受6-12个月标准诱导治疗后达到部分缓解或更好疗效、未接受ASCT的新诊断多发性骨髓瘤患者。
- 伊沙佐米口服,28天周期第1、8、15天给药,维持24个月,主要终点为随机化后的PFS。
主要发现
- 伊沙佐米组与安慰剂组3级及以上治疗中出现的不良事件发生率分别为36.6% vs 23.2%;因不良事件停药率分别为12.9% vs 8.0%。
- 常见任何级别不良事件包括恶心(26.8% vs 8.0%)、呕吐(24.2% vs 4.3%)、腹泻(23.2% vs 12.3%)。
- 新发原发性恶性肿瘤发生率无增加(5.2% vs 6.2%);研究期间死亡率分别为2.6% vs 2.2%。
临床怎么用
- 对于未接受ASCT且诱导后达到部分缓解或更好疗效的新诊断多发性骨髓瘤患者,可考虑伊沙佐米单药维持治疗24个月。
- 治疗期间需关注恶心、呕吐、腹泻等胃肠道不良事件,并监测3级及以上不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorable toxicity are needed. PATIENTS AND METHODS: The phase III, double-blind, placebo-controlled TOURMALINE-MM4 study randomly assigned (3:2) patients with NDMM not undergoing ASCT who achieved better than or equal to partial response after 6-12 months of standard induction therapy to receive the oral proteasome inhibitor (PI) ixazomib or placebo on days 1, 8, and 15 of 28-day cycles as maintenance for 24 months. The primary endpoint was PFS since time of randomization. RESULTS: Patients were randomly assigned to receive ixazomib (n = 425) or placebo (n = 281). TOURMALINE-MM4 met its primary endpoint with a 34.1% reduction in risk of progression or death with ixazomib versus placebo (median PFS since randomization, 17.4 v 9.4 months; hazard ratio [HR], 0.659; 95% CI, 0.542 to 0.801; P < .001; median follow-up, 21.1 months). Ixazomib significantly benefitted patients who achieved complete or very good partial response postinduction (median PFS, 25.6 v 12.9 months; HR, 0.586; P < .001). With ixazomib versus placebo, 36.6% versus 23.2% of patients had grade ≥ 3 treatment-emergent adverse events (TEAEs); 12.9% versus 8.0% discontinued treatment because of TEAEs. Common any-grade TEAEs included nausea (26.8% v 8.0%), vomiting (24.2% v 4.3%), and diarrhea (23.2% v 12.3%). There was no increase in new primary malignancies (5.2% v 6.2%); rates of on-study deaths were 2.6% versus 2.2%. CONCLUSION: Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with NDMM not undergoing ASCT. To our knowledge, this is the first PI demonstrated in a randomized clinical trial to have single-agent efficacy for maintenance and is the first oral PI option in this patient population.
引用
- Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020. PMID: 33021870. doi:10.1200/JCO.20.02060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。